Boston Scientific Corporation (NYSE:BSX)‘s stock had its “hold” rating restated by investment analysts at Oppenheimer Holdings, Inc. in a research report issued on Wednesday.

A number of other equities analysts also recently issued reports on BSX. Guggenheim reiterated a “buy” rating on shares of Boston Scientific Corporation in a report on Wednesday, April 12th. Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “hold” rating in a report on Monday, April 24th. TheStreet upgraded shares of Boston Scientific Corporation from a “c+” rating to a “b” rating in a report on Tuesday, April 25th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target (up previously from $29.00) on shares of Boston Scientific Corporation in a report on Thursday, April 27th. Finally, Evercore ISI increased their price target on shares of Boston Scientific Corporation from $26.50 to $28.50 and gave the company an “outperform” rating in a report on Friday, April 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $30.06.

Boston Scientific Corporation (NYSE:BSX) traded up 0.23% during mid-day trading on Wednesday, hitting $26.57. 3,405,143 shares of the stock were exchanged. The company has a 50-day moving average price of $27.55 and a 200-day moving average price of $25.94. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $28.51. The company has a market cap of $36.41 billion, a P/E ratio of 47.53 and a beta of 1.09.

Boston Scientific Corporation (NYSE:BSX) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.01. The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.04% and a return on equity of 23.62%. The business’s revenue was up 6.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.27 EPS. Analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Boston Scientific Corporation (NYSE:BSX) Earns Hold Rating from Oppenheimer Holdings, Inc.” was first published by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dailypolitical.com/2017/08/09/boston-scientific-corporation-nysebsx-earns-hold-rating-from-oppenheimer-holdings-inc.html.

In other news, CFO Daniel J. Brennan sold 92,158 shares of Boston Scientific Corporation stock in a transaction dated Tuesday, July 11th. The shares were sold at an average price of $27.48, for a total transaction of $2,532,501.84. Following the completion of the sale, the chief financial officer now directly owns 235,421 shares in the company, valued at $6,469,369.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP John Bradley Sorenson sold 7,900 shares of Boston Scientific Corporation stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $26.37, for a total transaction of $208,323.00. Following the sale, the senior vice president now owns 21,680 shares of the company’s stock, valued at $571,701.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 236,489 shares of company stock valued at $6,440,888. Insiders own 0.74% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Wetherby Asset Management Inc. boosted its stake in Boston Scientific Corporation by 6.7% in the first quarter. Wetherby Asset Management Inc. now owns 13,265 shares of the medical equipment provider’s stock valued at $330,000 after buying an additional 835 shares in the last quarter. Breton Hill Capital Ltd. bought a new stake in Boston Scientific Corporation during the first quarter valued at about $224,000. ProShare Advisors LLC boosted its stake in Boston Scientific Corporation by 1.2% in the first quarter. ProShare Advisors LLC now owns 136,230 shares of the medical equipment provider’s stock valued at $3,388,000 after buying an additional 1,602 shares in the last quarter. Profund Advisors LLC boosted its stake in Boston Scientific Corporation by 15.3% in the first quarter. Profund Advisors LLC now owns 56,044 shares of the medical equipment provider’s stock valued at $1,394,000 after buying an additional 7,423 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. boosted its stake in Boston Scientific Corporation by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 36,315 shares of the medical equipment provider’s stock valued at $844,000 after buying an additional 1,535 shares in the last quarter. 92.08% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.